Physician profile
Karan J Singh
NPI 1700841970
$5,743.32
in general payments reported to CMS, 2019-2025
32 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $133 · 2021: $659 · 2022: $1,007 · 2023: $836 · 2024: $736 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697 · Travel and Lodging: $883 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.42 |
| Travel and Lodging | $883.09 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,788.92 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $780.55 | 2019-2025 | Xtandi, Myrbetriq |
| Abbvie INC. | $698.41 | 2019-2025 | Alloderm, Botox, Lupron Depot |
| Pfizer INC. | $305.09 | 2019-2025 | |
| Procept Biorobotics Corporation | $265.05 | 2022-2023 | Aquabeam Robotic System |
| Abiomed | $161.91 | 2022 | |
| Merck Sharp & Dohme LLC | $150.52 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Histosonics, INC. | $147.96 | 2024 | |
| Antares Pharma, INC. | $124.32 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Myovant Sciences INC. | $109.17 | 2021-2022 | |
| Telix Pharmaceuticals | $105.69 | 2024 | Illuccix |
| Urogen Pharma, INC. | $103.51 | 2022-2023 | Jelmyto |
| Biosense Webster, INC. | $101.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.28 | 2023 | |
| Allergan, INC. | $98.50 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $86.56 | 2019 | |
| Tolmar, INC. | $82.04 | 2023-2025 | Eligard |
| Sumitomo Pharma America, INC. | $78.97 | 2023-2024 | Gemtesa |
| Urovant Sciences INC | $63.51 | 2022 | |
| Axonics, INC. | $56.73 | 2021-2022 | |
| Halozyme INC | $49.32 | 2023 | |
| Endo Pharmaceuticals INC. | $47.96 | 2021-2023 | Xiaflex, Aveed |
| Accord Healthcare, INC. | $46.28 | 2024-2025 | |
| Boston Scientific Corporation | $36.09 | 2020 | |
| Palette Life Sciences, INC. | $26.47 | 2023 | |
| Immunitybio, INC. | $25.53 | 2025 | |
| Endo USA, INC. | $24.49 | 2024 | Aveed, Xiaflex |
| Bayer Healthcare Pharmaceuticals INC. | $24.23 | 2022 | |
| Calyxo, INC. | $16.67 | 2025 | Cvac Aspiration System |
| Travere Therapeutics, INC. | $13.22 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.89 | 2019 | |
| Acerus Pharmaceuticals Corporation | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karan Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.